Compare BLLN & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | CZR |
|---|---|---|
| Founded | 2016 | 1937 |
| Country | United States | United States |
| Employees | 713 | 15500 |
| Industry | Medical Specialities | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.1B |
| IPO Year | N/A | 2015 |
| Metric | BLLN | CZR |
|---|---|---|
| Price | $98.28 | $30.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $126.71 | $31.92 |
| AVG Volume (30 Days) | 784.7K | ★ 3.3M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,473,504,000.00 |
| Revenue This Year | $46.29 | $3.56 |
| Revenue Next Year | $30.14 | $2.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.03 |
| 52 Week Low | $61.96 | $17.86 |
| 52 Week High | $150.44 | $30.88 |
| Indicator | BLLN | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 57.13 |
| Support Level | $73.46 | $29.50 |
| Resistance Level | $108.50 | $30.86 |
| Average True Range (ATR) | 8.11 | 0.23 |
| MACD | -5.35 | 0.00 |
| Stochastic Oscillator | 15.41 | 87.84 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.